

- pharmacology of, 215e-6, 215e-7
for varicella, 1185–1186
for viral encephalitis, 897
for viral meningitis, 893
- Valdecoxib, 91t
- Valganciclovir
for CMV infection prophylaxis, 215e-8, 922, 1252t
for CMV infection treatment, 215e-2t, 1193, 1831
pharmacology of, 215e-8
resistance to, 215e-8
- Valgus, 2221, 2228, 2228f
- Valine metabolism disorders, 434e-3t
- Valley fever. *See* *Coccidioides* spp. infections
- Valproate/valproic acid
adverse effects of, 2594t
bone marrow suppression, 2556
common, 2718t
hair loss, 380
hepatotoxicity, 2023, 2028, 2556
mitochondrial defects and, 85e-9
neurologic, 2555t
obesity, 2392
rare, 2718t
systemic, 2555t
thrombocytopenia, 727t
zinc deficiency, 96e-9
- for bipolar disorder, 2718, 2718t
drug interactions of, 939t, 2555t
for epilepsy, 2552, 2555t, 2556
for migraine prevention, 2594t
for myoclonus, 2623
for new daily persistent headache, 111
overdosage/poisoning with, 473e-10t, 2766t
pharmacology of, 2555t, 2718t
for posthypoxic myoclonus, 1782
for status epilepticus, 2558f
for stiff-person syndrome, 618
for tardive dyskinesia, 2624
therapeutic monitoring of, 2766t
- Valrubicin, 576
- Valsalva maneuver
in autonomic dysfunction evaluation, 2640, 2640t, 2641t
for focal atrial tachycardia, 1477
heart murmurs and, 51e-7, 1450, 1450t
for PSVT, 1484
- Valsalva ratio, 2640, 2641t
- Valsartan, 1511–1512, 1512t, 1624t
- Valve area, measurement of, 1463
- Valvular heart disease. *See also specific conditions* in carcinoid syndrome, 564, 565
cardiac imaging in, 270e-15–16
drug-induced, 565
dyspnea in, 47e-3
global burden of, 1528–1529
multiple and mixed. *See* Multiple/mixed valvular heart disease
murmurs in, **51e-1**
natural history of, 1439
in polycystic kidney disease, 1852
in pregnancy, 47–48
radiation-induced, 621
in relapsing polycondritis, 2203–2204
- VAMP2 (synaptobrevin), 985
- vanA* gene, 961
- van Buchem's disease (hyperostosis corticalis generalisata), 426e-5
- Vancomycin
action of, 930, 931t
adverse effects of, 491, 727t, 938t, 942
cutaneous, 379, 381
fever, 138
nephrotoxicity, 1803
for asymptomatic GAS carriage, 966
for burn-wound infections, 166e-3
for *C. difficile* infections, 860, 860t, 861
for catheter-related bloodstream infections, 487, 487t
for clostridial infections, 991t, 994
for community-acquired pneumonia, 808t
dosage monitoring, 36
empirical uses of, 767t
for enterococcal infections, 975t
for epidural abscess, 767t, 780t
for febrile neutropenia, 103e-23, 491
for health care–associated pneumonia, 812t
indications for, 940t, 942
for infective endocarditis
as empirical therapy, 767t, 780t, 824
enterococcal, 821, 822t, 975t
staphylococcal, 822t, 823, 963
streptococcal, 822t
for intraabdominal infection, 767t
for intracranial infections, 780t
for lung abscess, 815
for meningitis
as empirical therapy, 767t, 780t, 887t
enterococcal, 975t
MRSA, 889t, 890
pneumococcal, 889, 952
for MRSA infections, 961, 962t, 963
community-acquired pneumonia, 808t
as empirical therapy, 767t
endocarditis, 823
meningitis, 889t, 890
skin, 832t
for necrotizing fasciitis, 832t
for nongonococcal bacterial arthritis, 835
for osteomyelitis, 840t, 841t
for postsplenectomy sepsis, 780t
in pregnancy and lactation, 937t
prophylactic, 945t
for purpura fulminans, 780t
resistance to. *See also* Vancomycin-resistant enterococci (VRE)
mechanisms of, 931t, 933–934, 961, 976
rates of, 940t, 942
for sepsis/septic shock, 767t, 780t, 1757t
for staphylococcal infections, 962t
therapeutic monitoring of, 2766t
for toxic shock syndrome, 780t, 963
- Vancomycin-intermediate *S. aureus* (VISA), 933, 961
- Vancomycin-resistant enterococci (VRE)
diagnosis of, 774
epidemiology of, 973
genomics of, 769t, 774
global considerations in, 973
in health care–associated infections, 973
laboratory identification of, 150e-8
mechanism of, 933–934, 976
treatment of, 975t
- van den Bergh reaction, 280
- Vandetanib, 102e-5t, 103e-18t, 2342
- van* gene, 774
- Vanilloids, 262e-4
- Vanishing bile duct syndrome, 284, 2027–2028
- VAP. *See* Ventilator-associated pneumonia (VAP)
- Vaptans (vasopressin antagonists)
for hyponatremia, 64e-5, 302, 2281–2282
for SIADH, 2282f, 2283
- Vardenafil
action of, 324, 325f, 326f
adverse effects of, 329t
characteristics of, 329t
contraindications to, 328, 329t
for erectile dysfunction, 328, 2672
for lower urinary tract symptoms, 587
- Varenicline, 507, 1705, 2732
- Variable expressivity, 436–437
- Variable number of tandem repeats (VNTRs), 441
- Variant of unknown significance (VUS), 433, 448
- Variceal bleeding
esophageal. *See* Esophageal varices
gastric, 346e-1v, 1891, 1891f, 2097
- Varicella (chickenpox), **1183**
clinical features of, 131t, 341t, 1184
extracutaneous, 1184
oral, 238t
skin
characteristics of, 131t, 134
evolution of, 25e-8f, 1184, 1184f
rash, 361t, 362
vesicles, 827
complications of, 1184, 2673
congenital, 1184
differential diagnosis of, 134, 1185
epidemiology of, 131t, 1183
health care–associated, 913
incidence pre- and postvaccine, U.S., 785t
infection control measures, 917
pathogenesis of, 1183
perinatal, 1184
prevention of, 1186, 1186t. *See also* Varicella vaccine
treatment of, 215e-7, 1185–1186
- Varicella vaccine
contraindications for, 789t
precautions for, 789t
recommended administration of
in adults, 29t, 787–788f
in children, 1186
for health care–associated exposure, 917
in pregnancy, 788f
storage and handling of, 791
- Varicella-zoster immune globulin (VZIG), 917, 1186, 1186t, 1252t
- Varicella-zoster virus (VZV), 342, 1183, 1185
- Varicella-zoster virus (VZV) infections. *See also* Herpes zoster (shingles); Varicella (chickenpox)
in cancer patient, 488, 492
encephalitis, 488, 894, 895t
etiology of, 1183
meningitis, 892
neuropathy in, 2685
pathogenesis of, 1183
prevention of, 1186, 1186t
in transplant recipient, 139e-4, 921, 921t
treatment of, 1185–1186
- Varicella-zoster virus (VZV) vaccine, 485t, 893, 921, 929, 1186
- Varicocele, 2360
- Varicose veins, 1650. *See also* Chronic venous disease
- Variegate porphyria (VP)
clinical features of, 361t, 362, 2522t, 2531, 2681
diagnosis of, 2522t, 2531
global considerations in, 2521, 2531, 2681
pathophysiology of, 2522f, 2681
vs. porphyria cutanea tarda, 362
treatment of, 2531, 2681
unsafe drugs in, 2526, 2527–2529t
- Variola virus, 261e-6. *See also* Smallpox
- Varioliform gastritis, 1931
- Varus, 2221, 2228, 2228f
- Vasa recta, 332e-2
- Vascular access-related infections. *See* Catheter-related bloodstream infections
- Vascular addresses, 102e-17f
- Vascular cell adhesion molecule-1 (VCAM-1), 89e-1, 1242, 2150
- Vascular dementia, 170, 172, 173t, 2602
- Vascular disease. *See also specific diseases*
aging and, 94e-4
gene therapy in, 91e-4
ophthalmological manifestations of, 41e-1v
- Vascular ectasias
bleeding in, 277
diagnosis of, 1891, 1892f
treatment of, 1897, 1897f
- Vascular endothelial growth factor (VEGF)
in diabetic retinopathy, 2424
in gene therapy, 91e-4
in high-altitude illness, 476e-1
in kidney development, 332e-1
in preeclampsia, 45
in stem cell therapy, 90e-3
in systemic sclerosis, 2156
in tumor angiogenesis, 102e-14–15, 102e-14f, 102e-15f, 102e-16f
- Vascular endothelial growth factor (VEGF) antibodies, 103e-21, 103e-21t
- Vascular endothelial growth factor (VEGF) inhibitors, 91e-4
- Vascularization, in tissue engineering, 92e-1
- Vascular mimicry, 102e-13
- Vascular resistance, 1463
- Vascular tone, 265e-4